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Background: Over 1900 mutations have been identified in the cystic fibrosis conductance transmembrane
regulator gene, including single nucleotide substitutions, insertions, and deletions. Unidentified mutations may
still lie in introns or in regulatory regions, which are not routinely investigated, or in large genomic deletions,
which are not revealed by conventional molecular analysis. The apparent homozygosity for a rare, cystic fibrosis
conductance transmembrane regulator mutation screened by standard molecular analysis should be further
investigated to confirm if the mutation is in fact homozygous. We describe a patient presenting with an
apparent homozygous S4X mutation.
Case presentation: A 13-year-old female patient of African descent with clinical symptoms of classic cystic
fibrosis and a positive sweat test (97 mEq/L, diagnosed at age 3 years) presented with pancreatic insufficiency
and severe pulmonary symptoms (initial lung colonization with Pseudomonas aeruginosa at age 4 years; forced vital
capacity: 69%; forced expiratory volume: 51%; 2011). Furthermore, she developed severe acute lung disease and
recurrent episodes of dehydration requiring hospitalization. The girl carried the CFTR mutation S4X in apparent
homozygosity. However, further analysis revealed a large deletion in the second allele that included the region of
the mutation. The deletion that we describe includes nucleotides 120–142, which correspond to a loss of 23
nucleotides that abolishes the normal translation initiation codon.
Conclusion: This study reiterates the view that large, cystic fibrosis conductance transmembrane regulator
deletions are an important cause of severe cystic fibrosis and emphasizes the importance of including large
deletions/duplications in cystic fibrosis conductance transmembrane regulator diagnostic tests.
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Cystic fibrosis (CF; Omin #219700), the most frequent, life-
limiting autosomal recessive disorder among Caucasians, is
caused by mutations in the cystic fibrosis conductance
transmembrane regulator (CFTR) gene [1]. In Europe, the
carrier frequency is 1:25, resulting in a disease incidence
of 1 in 2500 live births [2]. However, this incidence is quite
variable, with a range from 1/500 in Ohio Amish to 1/* Correspondence: gkalil.fiocruz@gmail.com
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article, unless otherwise stated.90000 in Hawaiian Orientals [3]. The CFTR gene is
characterized by an extremely large number of mutations
(more than 1900) [4], the most common being the F508del.
Other disease-causing mutations are distributed throughout
all regions of the world, often with very low frequencies,
making the molecular diagnosis difficult, especially in
countries outside the European axis where the F508del
frequency is relatively low, as observed in countries where
ethnic composition is not predominantly Caucasian. Brazil
is a typical example where the molecular diagnosis of CF
is difficult owing to its multi-ethnic characteristics with a
significant African component.Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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is usually based on the mutation panel of European or
North American populations, which is unsuitable for
Brazil. Little is known about the incidence of CF in
Brazil, but it does vary among different regions of the
country [5-8]. Among the European countries that con-
tributed to the current ethnic composition of our popu-
lation, the F508del allele frequency is 71.8% in Germany,
51% in Italy, 53% in Spain, 57% in Poland, 58% in
Slovenia, and 45% in Portugal; the latter is the main
Brazilian Caucasian component [9,10]. The migratory
waves from different regions of Europe, the intense
inter-ethnic gene flow and different proportions of
mixing genes of Caucasian, African, and Amerindian ori-
gins may explain the variation in the prevalence of the
F508del mutation among different Brazilian regions [11].
Over the past 10 years, the F508del mutation contrib-
uted 30% of CF alleles in the State of Rio de Janeiro and
disease incidence was estimated at 1/6902 live births
[12]. Given the current annual number of births of
220,603 (Records of the Ministry of Health of Brazil,
2011; http://www2.datasus.gov.br/DATASUS/index.php),
approximately 32 patients are born with CF each year.
Until now, mutation screening allowed us to identify 29
different mutant alleles in CF patients from Rio de
Janeiro. However, the detection rate is only 60%, which
means that 40% of alleles remain unknown.
Over 1900 mutations have been identified throughout
the CFTR gene, including single nucleotide substitutions,
insertions, and deletions. Unidentified mutations may
still lie in introns or in regulatory regions, which are not
routinely investigated, or in large genomic deletions,
which are not revealed by conventional molecular ana-
lysis. The apparent homozygosity for a rare CFTR muta-
tion screened by standard molecular analysis should be
further investigated to confirm if the mutation is in fact
homozygous. Apparent homozygosity can result from a
mutation of one allele and the presence of a large dele-
tion encompassing the location of the first mutation on
the second allele [13].
We describe a patient carrying the S4X mutation
(CM930095) in apparent homozygosity; further analysis
revealed that it was heterozygous with a large deletion
that includes nucleotides 120–142, which corresponds to
a loss of 23 nucleotides coding the first exon of the
CFTR gene. This deletion removes a region from pos-
ition -12 to position 10, including codons 1, 2, 3, and 4
of exon 1.
Case presentation
A 13-year-old female patient of African descent with
clinical symptoms of classic CF, a positive sweat test
(97 mEq/L; diagnosed at age 3 years), pancreatic insuffi-
ciency (PI), and severe pulmonary symptoms (initial lungcolonization with Pseudomonas aeruginosa at the age of
4 years) had a forced vital capacity of 69% and a forced
expiratory volume of 51%. Furthermore, the girl devel-
oped severe acute lung disease and recurrent episodes of
dehydration requiring hospitalization.
Methods
Informed consent in CFTR studies was obtained from
the proband and her parents at the time of referral.
Genomic DNA was extracted from peripheral blood by a
Purelink Genomic DNA Mini Kit (Invitrogen, Carlsbad,
CA, USA). The DNA was tested for a proper panel of
CFTR mutations from Rio de Janeiro [6] and the S4X
mutation in apparent homozygosity was identified by
allele-specific polymerase chain reaction (PCR) amplifi-
cation. The apparent homozygosity for a rare mutation
and the absence of the S4X mutant allele in the maternal
DNA raised the suspicion that it was a false homozygosity.
To evaluate the presence of a large deletion encompassing
the same sequence region, amplified products were cloned
using the pGEM-T® Easy Vector System (Fitchburg
WI, USA) following manufacturer recommendations and
all plasmids were purified by QIAprep® Spin Miniprep
Kit (Qiagen, GmbH, Hilden) . Purified plasmids were
sequenced by Sanger protocol with the BigDye® Ter-
minator v3.1 Cycle Sequencing Kit (Applied Biosystems,
Foster City CA, USA) according to the manufacturer’s
instructions. Single nucleotide polymorphism from intra-
genic markers (TUB9-T854T-M470V) were genotyped
using TaqMan® allelic discrimination assays (Assay ID:
C__59055676_10; C___3021356_10; C___3021372_10, re-
spectively, Applied Biosystems). The TaqMan® genotyping
reaction was amplified on an Applied Biosystems® 7500
Fast Real-Time PCR System.
Results
The suspected presence of a large deletion in exon 1 was
confirmed by cloning and sequencing analysis, perfor-
med on the DNA samples from both parents and the
patient (Figure 1). This deletion removes 23 nucleotides
from position 120–142, which affects the 5’ untranslated
region upstream of exon 1, including the translation
initiation codon (codons 133–135). This result confirms
our initial suspicion that the patient was compound het-
erozygous for one rearrangement, instead of being homo-
zygous for a rare allele. Analysis of intragenic markers
showed that she was homozygous for the 2-1-2 (TUB9-
T854T-M470V) haplotype.
Discussion
When a rare mutation is detected in homozygosity in a
molecular analysis the result should be confirmed. The
distinction between real and apparent homozygosity has
important implications for genetic counseling, prenatal
Figure 1 Sequence comparison and alignment between the wt-CFTR sequence (middle capital letters) with the proband sequence
eletropherograms. Paternal chromosome (upper sequence) showing the change C to A corresponding to the S4X mutation; and maternal
chromosome (lower sequence) with the 23 nucleotides deleted corresponding to the c.120del23-CFTR mutation.
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molecular analysis identifies a rare mutation in the
CFTR gene in apparent homozygosity, the patient should
be tested for large deletions/duplications to avoid a false
diagnosis. Until the true pathogenic nature of this CFTR
mutation can be determined, the penetrance or segrega-
tion within the family and the effect on protein function
cannot be confirmed with absolute confidence [13].
This case highlights the limitations of current molecu-
lar diagnosis tests based on PCR to detect large deletions
in the heterozygous state. The patient experienced several
episodes of lower respiratory tract infections with airway
pathogen colonization (P. aeruginosa, Staphylococcus
aureus, Burkholderia cepacea complex). She had insuf-
ficient pancreatic exocrine function with visible elimin-
ation of fat in feces and polyps in the gallbladder. In
this case, the S4X in compound heterozygosity with
c.-12_10del23 results in a severe phenotype. Allelic
frequencies of the S4X and c.-12_10del23 for 618 CF
chromosomes were 0.6% and 0.2%, respectively. The
120del23 mutation was first identified in two CF patients
from the Azores [14]. Analysis of CFTR markers conforms
with our previous findings about “risk” haplotypes associ-
ated with non-F508del mutations and by the intense gene
flow among different ethnic groups that contributed to
the Brazilian population composition [6,15].
The c.-12_10del23 mutation that we describe here was
first detected in one Portuguese CF patient and sub-
mitted to the Cystic Fibrosis Mutation Database [4]
by Ramalho and colleagues [12]. A PROVEAN scoreof −3.655 (cutoff = −2.5) for c.1-10delATGCAGAGGT
confirms the deleterious characteristic for this deletion
[16]. A possible effect is the activation of a potential
downstream translation initiation site with a new reading
frame, like that demonstrated by Ramalho and colleagues
in subsequent studies to functionally characterize the ef-
fect of this mutation. They revealed that the c.-12_10del23
mutation results in drastically reduced protein function
and shows good correlation with the severe clinical CF
phenotype [14]. Our observations are consistent with this
finding, where the presence of two severe CFTRmutations
leads to severe clinical features in the patient and suggests
a reduced function of the protein. Other studies are neces-
sary to better understand the association between these
mutations and their pathogenesis.
Conclusions
This study reiterates the view that large CFTR deletions
are an important cause of severe CF and emphasizes the
importance of including large deletions/duplications in
the diagnosis of CFTR mutations when standard proce-
dures reveal the presence of just one mutation, especially
if that mutation is rare.
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